Galux, an artificial intelligence (AI) drug development company, announced on June 24 that its bispecific antibody immunotherapy, designed using its proprietary AI protein engineering platform "GaluxDesign," has been selected as a new candidate substance project at the candidate substance stage for the National New Drug Development Project, which is overseen by the National New Drug Development Agency.


This selection is significant because it confirms the technological potential, development necessity, and commercial viability of an innovative drug candidate designed by AI, following evaluation by new drug development experts.

The PD-1/IL-18v bispecific antibody designed with Galaxy Design overcomes immune suppression (IL-18BP) and activates T cells to eliminate cancer cells. Galaxy

The PD-1/IL-18v bispecific antibody designed with Galaxy Design overcomes immune suppression (IL-18BP) and activates T cells to eliminate cancer cells. Galaxy

View original image

The National New Drug Development Project is an inter-ministerial national R&D initiative launched to strengthen the global competitiveness of Korea's pharmaceutical and biotechnology industries. Since 2021, over a 10-year period, the program has supported all stages of new drug development, aiming to reinforce the domestic R&D ecosystem, generate globally practical outcomes, and deliver public benefits in the healthcare sector.


This project aims to develop next-generation immuno-oncology drug candidates for cancer patients who do not respond sufficiently to existing immunotherapies or who have developed resistance. The development target is a bispecific antibody candidate, PD-1/IL-18v, which combines an AI-designed IL-18 variant with a PD-1 antibody.


Although IL-18 is a promising cytokine capable of inducing robust anti-cancer immune responses, therapeutic development has been limited due to in vivo inhibition and concerns about systemic toxicity. Galux leveraged its proprietary AI protein engineering technology to redesign the structure and function of IL-18, overcoming these limitations and enabling the selective induction of immune responses within the tumor microenvironment. This variant is based on the AI-designed bispecific antibody immunotherapy research results released at AACR 2026.


Through this project, Galux plans to advance its AI-based bispecific antibody candidate, developed at the design stage, to preclinical validation, and to comprehensively assess its potential as an actual new drug asset.


Chaok Seok, CEO of Galux, stated, "The most significant aspect of this selection is that an innovative drug candidate designed by AI has been evaluated by new drug development experts and has received national support to progress to the candidate substance development stage. This is an important example demonstrating that AI can go beyond merely proposing candidates to actually creating innovative new drug assets."



He added, "Galux will continue to utilize its AI drug development platform to discover innovative drug candidates that can ultimately lead to patient treatments. Through this project, we will accelerate the preclinical validation of the AI-designed IL-18 variant-based bispecific antibody candidate and further develop it as a next-generation immunotherapy."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing